Hemiconvulsion–Hemiplegia–Epilepsy Syndrome: Disease-Characteristics Report

Executive summary

Hemiconvulsion–hemiplegia–epilepsy (HHE) syndrome is a rare, acquired, predominantly pediatric destructive encephalopathy/epilepsy syndrome. Its defining sequence is: (1) prolonged unilateral clonic status epilepticus, usually during fever; (2) immediate or early persistent contralateral hemiplegia; and (3) delayed focal epilepsy, often accompanied by unilateral cerebral atrophy. The evidence base remains limited mainly to retrospective cohorts, imaging series, surgical series, and case reports; there are no disease-specific randomized trials, validated molecular biomarkers, or robust population incidence estimates.

Open Targets recognizes the related entity “idiopathic hemiconvulsion-hemiplegia syndrome,” MONDO:0019485, but lists zero associated targets, consistent with the syndrome not having an established single molecular cause. The exact ontology boundary between hemiconvulsion–hemiplegia syndrome and full HHE syndrome should be checked in each resource before automated cross-mapping. (OpenTargets Search: hemiconvulsion-hemiplegia-epilepsy syndrome)

Table: This table summarizes the most actionable disease-knowledge findings for Hemiconvulsion-Hemiplegia-Epilepsy syndrome and explicitly marks where evidence is based on classic clinical literature versus current gaps. It is useful for rapid knowledge-base curation because it links core syndrome features to ontology suggestions and highlights missing trials, targets, and omics data.

1. Disease information

Definition and classification

HHE is an acquired sequence rather than a conventional inherited epilepsy syndrome. The initial “hemiconvulsion” is prolonged focal motor—usually hemiclonic—status epilepticus. It produces or accompanies acute unilateral hemispheric injury, after which the child has contralateral hemiplegia or severe hemiparesis. Chronic focal epilepsy may emerge after a latent interval.

The term hemiconvulsion–hemiplegia (HH) syndrome is appropriately used before recurrent unprovoked epilepsy appears; HHE syndrome denotes completion of the three-stage sequence. “Idiopathic” historically indicated absence of a demonstrable antecedent structural lesion, infection, or metabolic disorder, not proof of a primary genetic disease.

Identifiers and synonyms

Synonyms: HHE syndrome; hemiconvulsion–hemiplegia–epilepsy syndrome; hemiconvulsion–hemiplegia syndrome; HH syndrome; idiopathic hemiconvulsion–hemiplegia syndrome; infantile hemiconvulsion–hemiplegia and epilepsy syndrome; historically, hemiplegia–hemiconvulsion–epilepsy syndrome.

Data provenance

The description is derived from aggregated disease-level literature, including small retrospective cohorts and imaging series—not from a single patient’s EHR. Major sources include the classic description by Gastaut et al. (1959), the review by Auvin et al. (published September 2012; DOI), and the 35-patient clinical/imaging/EEG series by Albakaye et al. (published March 2018; DOI).

2. Etiology

Primary causal factors

The proximate trigger is generally prolonged unilateral status epilepticus in the immature brain, frequently associated with fever or an acute infection. HHE can also occur in association with pre-existing structural, metabolic, inflammatory, or genetic neurologic disease; such cases are better described as secondary HHE phenotypes.

Reported associations include CNS or systemic infection, congenital adrenal hyperplasia, L-2-hydroxyglutaric aciduria, tuberous sclerosis complex, 1q44 deletion, leukodystrophy, and Dravet syndrome. These heterogeneous associations support HHE as a final common clinicoradiologic pathway, not a unitary etiologic disease.

Risk factors

• Age: infancy and early childhood, when fever-provoked seizures and the immature brain’s susceptibility to excitotoxic edema are greatest.
• Seizure duration and refractoriness: prolonged focal motor status is the most consistent modifiable risk factor.
• Hyperthermia/fever: likely lowers seizure threshold and may amplify seizure-mediated metabolic injury. Experimental work shows that hyperthermia aggravates epileptic brain injury, whereas hypothermia reduces it; this is supportive animal evidence, not HHE-specific clinical proof (Lundgren et al., DOI).
• Underlying neurologic disease: structural lesions, metabolic disorders, encephalitis/encephalopathy, or developmental and epileptic encephalopathies can predispose to the same sequence.
• SCN1A: variants occur in a minority of reported HHE patients and can indicate a Dravet-spectrum phenotype rather than primary HHE. Kim et al. explicitly reported a “low incidence of SCN1A genetic mutation” (published October 2013; DOI).

No reproducible sex, ancestry, lifestyle, toxin, occupational, smoking, alcohol, or dietary risk factor has been established.

Protective factors

No validated protective allele, diet, supplement, or long-term prophylactic drug has been demonstrated. The most biologically plausible protection is rapid termination of prolonged seizures, maintenance of oxygenation, perfusion, glucose, electrolytes, and normothermia, and prompt treatment of infection. These are standards of status-epilepticus care rather than HHE-specific trial results.

Gene–environment interaction

A reasonable model is that genetic seizure susceptibility—particularly an SCN1A-related fever-sensitive epilepsy or another developmental epilepsy—interacts with fever and prolonged status to cross a threshold for unilateral excitotoxic injury. This remains a susceptibility model; there is no validated polygenic score, modifier locus, or quantified interaction effect.

3. Phenotypes

Reliable phenotype percentages cannot be generalized: by definition, hemiconvulsion and hemiplegia are near-obligate, whereas delayed epilepsy, cognitive impairment, language deficit, and drug resistance vary substantially among small and selected cohorts.

Quality of life

Persistent unilateral weakness affects ambulation, bimanual activity, dressing, feeding, school participation, and independence. Chronic epilepsy adds medication burden, injury risk, supervision requirements, and psychosocial stress. Cognitive and language impairment may dominate educational outcome. No HHE-specific EQ-5D, PROMIS, SF-36, or validated disease-specific quality-of-life study was identified.

4. Genetic and molecular information

HHE has no established defining causal gene, inheritance pattern, penetrance estimate, carrier frequency, founder variant, or recurrent pathogenic chromosomal abnormality. Open Targets reports no disease-associated target for the mapped idiopathic HH entity. (OpenTargets Search: hemiconvulsion-hemiplegia-epilepsy syndrome)

Reported genetic findings

• SCN1A—HGNC:10585; OMIM gene 182389—has been investigated because prolonged fever-triggered hemiclonic seizures are characteristic of Dravet syndrome. Variants are uncommon in clinically diagnosed HHE and should prompt reassessment for a Dravet-spectrum disorder.
• 1q44 microdeletion has been described in a single HHE case; causality was explicitly uncertain (Gupta et al., January 2014).
• Individual secondary cases associated with monogenic/metabolic disorders do not establish those genes as causes of idiopathic HHE.

There are no HHE-specific curated variant lists, recurrent pathogenic alleles, allele-frequency estimates, somatic drivers, established modifier genes, epigenetic signatures, methylation episignatures, or chromosomal hotspots. Variant classification should therefore be assigned to the underlying diagnosed genetic disease, not to HHE itself.

5. Environmental information

Fever and acute infection are common seizure precipitants. Reported infections include routine febrile illnesses and isolated cases associated with influenza, HHV-6-related illness, and COVID-19/multisystem inflammatory syndrome. Infection may act through fever, cytokine signaling, altered blood–brain-barrier function, or direct encephalitis; pathogen detection does not automatically establish direct brain infection.

No consistent role is established for pollution, radiation, pesticides, heavy metals, occupation, smoking, alcohol, exercise, or nutrition. Lifestyle variables are largely inapplicable because onset usually occurs in very young children.

6. Mechanism and pathophysiology

Proposed causal chain

1. Upstream trigger: fever/infection or another acute cerebral stressor in a susceptible young child.
2. Prolonged unilateral seizure activity: sustained excitatory firing markedly increases ATP and oxygen demand.
3. Ionic and transmitter failure: glutamate-dependent excitation, sodium and calcium entry, potassium disequilibrium, and impaired Na⁺/K⁺-ATPase activity produce cytotoxic edema.
4. Neurovascular dysfunction: hyperperfusion may initially compensate, but autoregulatory failure, blood–brain-barrier disruption, vasogenic edema, and relative hypoxia/ischemia can follow.
5. Secondary injury: mitochondrial dysfunction, reactive oxygen species, protease activation, inflammation, microglial and astrocytic activation, apoptosis/necrosis, and axonal injury expand the lesion.
6. Clinical hemiplegia: injury to unilateral motor cortex, subcortical white matter, basal ganglia, or corticospinal pathways causes contralateral weakness.
7. Chronic remodeling: neuronal loss, gliosis, hemispheric atrophy, and abnormal network reorganization create an epileptogenic substrate, producing delayed focal epilepsy.

The relative contributions of seizure-mediated excitotoxicity, inflammation, perfusion failure, venous congestion, and pre-existing vulnerability differ between patients. Pathology has shown inflammatory-degenerative changes, but no single protein dysfunction or enzyme deficiency defines HHE. A pathology/MRI report with mechanistic implications was published by Auvin et al. in June 2007 (DOI); inflammatory-degenerative histology was also reported by Serino et al. in May 2014 (DOI).

Ontology suggestions

• GO biological process: glutamatergic synaptic transmission (GO:0035249), regulation of membrane potential (GO:0042391), response to hypoxia (GO:0001666), inflammatory response (GO:0006954), microglial activation (GO:0001774), reactive oxygen species metabolic process (GO:0072593), neuron apoptotic process (GO:0051402), gliosis (GO:0042063).
• Cell Ontology: glutamatergic neuron (CL:0000679), GABAergic neuron (CL:0000617), astrocyte (CL:0000127), microglial cell (CL:0000129), oligodendrocyte (CL:0000128), brain vascular endothelial cell, pericyte.
• GO cellular components: synapse (GO:0045202), postsynaptic membrane (GO:0045211), mitochondrion (GO:0005739), axon (GO:0030424), myelin sheath (GO:0043209), blood–brain barrier-associated junctions.

Molecular profiling and advanced technologies

No disease-specific validated transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, CRISPR-screen, or integrated multi-omics dataset was identified. Cytokines, diffusion metrics, and injury proteins remain investigational rather than diagnostic biomarkers.

7. Anatomical structures affected

The central nervous system, particularly one cerebral hemisphere, is primary. Acute abnormalities can involve cortex, subcortical white matter, hippocampus, basal ganglia, thalamus, and corticospinal projections. Chronic findings include unilateral cortical and white-matter volume loss, ventricular enlargement ex vacuo, gliosis, and possible Wallerian degeneration.

Suggested anatomy terms include cerebral hemisphere (UBERON:0001869), cerebral cortex (UBERON:0000956), cerebral white matter (UBERON:0002437), hippocampal formation (UBERON:0002421), basal ganglion (UBERON:0002420), thalamus (UBERON:0001897), and corticospinal tract. Laterality is essential: seizures and hemispheric MRI injury are generally ipsilateral, while hemiplegia is contralateral.

Secondary musculoskeletal consequences include unilateral spasticity, reduced limb growth/use, contracture, hip displacement, scoliosis, and impaired gait; these are complications of upper-motor-neuron injury rather than primary multiorgan disease.

8. Temporal development

• Onset: acute, usually in infancy or early childhood.
• Acute phase: prolonged hemiclonic status, often febrile; altered consciousness may persist after motor convulsions stop.
• Early postictal phase: hemiplegia becomes evident. MRI may initially be normal, but typically develops unilateral swelling, T2/FLAIR hyperintensity, and diffusion restriction.
• Evolution over weeks to months: edema resolves and unilateral atrophy/gliosis emerges. Longitudinal MRI findings in ten children were reported by Barcia et al. (published December 2013; DOI).
• Chronic phase: fixed or partially improving hemiparesis; delayed focal seizures may arise after months or years and persist lifelong.

The critical intervention window is the initial status episode: seizure termination and prevention of systemic secondary insults must occur within minutes, not after imaging changes become established.

9. Inheritance and population

No reliable prevalence per 100,000 or annual incidence estimate is available. Published evidence includes individual cases, a 10-child longitudinal MRI cohort, a 35-case clinical/imaging/EEG series, and regional retrospective series. These cannot establish population frequency and are vulnerable to referral and survivor bias.

HHE is not normally inherited. Consequently, Mendelian penetrance, anticipation, carrier frequency, founder effects, consanguinity, and germline mosaicism are not applicable unless an underlying genetic disorder is identified. No reproducible sex ratio, ancestry enrichment, or endemic geographic distribution is established. Apparent regional clusters may reflect infection burden, treatment access, or ascertainment rather than population genetics.

10. Diagnostics

Clinical approach

Diagnosis is clinicoradiologic and longitudinal. The essential history is prolonged unilateral convulsive status followed by persistent contralateral motor deficit. Delayed recurrent focal seizures complete the HHE sequence.

Acute investigations should include:

• continuous or repeated EEG, particularly when consciousness does not recover, to exclude ongoing nonconvulsive status;
• urgent MRI brain with DWI/ADC, T2/FLAIR, susceptibility imaging, and vascular sequences; CT is useful when MRI is unavailable but is less sensitive;
• glucose, electrolytes, calcium, magnesium, blood count, liver/renal tests, inflammatory markers, cultures, and toxicology as indicated;
• lumbar puncture with microbiology/virology and autoimmune studies when safe and clinically indicated;
• metabolic testing—lactate, ammonia, plasma amino acids, acylcarnitines, urine organic acids—when presentation, imaging, or family history suggests a metabolic disorder.

The characteristic radiologic evolution is acute unilateral hemispheric edema/restricted diffusion followed by cerebral hemiatrophy. Freeman et al. described “characteristic early magnetic resonance imaging findings” (published January 2002; DOI). A normal very-early MRI does not exclude HHE.

Genetic testing

Genetic testing is not required to confirm acquired HHE, but is appropriate when there was prior developmental abnormality, recurrent fever-sensitive seizures, family history, dysmorphism, congenital anomalies, metabolic clues, or atypical/bilateral imaging.

A practical sequence is an epilepsy/developmental-encephalopathy panel including SCN1A, or trio exome/genome sequencing where phenotype is nonspecific. Chromosomal microarray is reasonable for congenital anomalies or intellectual disability. Mitochondrial, repeat-expansion, karyotype, and FISH testing are not routine unless specifically indicated. No HHE-specific liquid biopsy or omics diagnostic is available.

Differential diagnosis

• Dravet syndrome: recurrent fever-sensitive hemiclonic/generalized seizures, often SCN1A-related; early MRI is usually normal and fixed unilateral destructive injury is not required.
• Rasmussen encephalitis: progressive focal seizures, epilepsia partialis continua, and gradually progressive unilateral atrophy rather than a single catastrophic febrile hemiclonic episode.
• Arterial ischemic stroke/cerebral venous thrombosis: vascular-territory or venous imaging abnormality; seizure may be a consequence rather than the primary insult.
• Encephalitis/encephalopathy, FIRES/NORSE, or AESD: generally more diffuse or multifocal seizure burden/imaging, although overlap exists.
• Alternating hemiplegia of childhood: recurrent reversible hemiplegic attacks, often ATP1A3-related, rather than fixed post-status deficit with hemiatrophy.
• MELAS and metabolic stroke-like disorders: recurrent nonvascular-territory lesions, lactic acidosis, multisystem features.
• Todd paresis: transient and resolves, without progressive hemispheric atrophy.
• Structural focal epilepsy: pre-existing malformation or lesion should be distinguishable on baseline/serial imaging.

There is no asymptomatic population, newborn, carrier, or cascade screening program for HHE.

11. Outcome and prognosis

No validated 5- or 10-year survival rate or disease-specific life-expectancy estimate exists. Death can occur during catastrophic status, cerebral edema, or systemic complications, but most literature emphasizes chronic morbidity.

Important long-term outcomes are persistent hemiparesis/spasticity, developmental and intellectual disability, language impairment, visual-field loss, orthopedic complications, and chronic—sometimes drug-resistant—focal epilepsy. Motor recovery is variable; complete recovery is less likely when early weakness is profound and MRI shows extensive cortex, deep nuclei, and white-matter injury.

Plausible adverse prognostic factors include longer/refractory status, delayed seizure control, extensive diffusion restriction, deep-gray involvement, severe edema or raised intracranial pressure, contralateral abnormalities, underlying encephalopathy, and subsequent high seizure burden. None is a clinically validated HHE prognostic biomarker.

12. Treatment

Acute treatment

Treatment follows pediatric convulsive status-epilepticus protocols:

1. Airway, breathing, circulation; check glucose; correct hypoxia, hypotension, electrolyte disturbances, and hyperthermia.
2. Prompt benzodiazepine.
3. Rapid second-line antiseizure medication—commonly levetiracetam, fosphenytoin/phenytoin, or valproate, selected according to age, comorbidity, and suspected syndrome.
4. Refractory status: pediatric neurocritical care, continuous EEG, anesthetic infusion and/or additional agents according to protocol.
5. Treat suspected CNS infection empirically until excluded; manage intracranial pressure and severe edema with neurocritical-care/neurosurgical input.

Suggested intervention ontologies are NCIT concepts for Anticonvulsant Therapy, Benzodiazepine, Levetiracetam, Fosphenytoin, Valproic Acid, Mechanical Ventilation, and Intensive Care; exact NCIT codes should be verified in the target terminology release. Relevant chemical annotation examples include diazepam (CHEBI:49575), lorazepam (CHEBI:6539), and valproic acid (CHEBI:39867).

No agent has been proven to prevent hemispheric atrophy after the initial seizure. Therapeutic hypothermia, corticosteroids, IVIG, cytokine blockade, and other neuroprotective approaches are not established HHE therapies.

Chronic treatment and rehabilitation

Antiseizure medication is individualized to seizure type and underlying etiology. Physical, occupational, speech/language, neuropsychological, visual, and orthopedic care should start early. Spasticity may require stretching, orthoses, botulinum toxin, oral antispastic medication, casting, or orthopedic surgery.

For disabling drug-resistant epilepsy arising from a severely injured hemisphere, multidisciplinary presurgical evaluation may support functional hemispherectomy or hemispherotomy. Kim et al. reported surgical treatment of delayed epilepsy in HHE (published May 2008; DOI). Evidence is observational; surgery trades existing or anticipated hemispheric disconnection deficits against seizure control.

A small report described ACTH for intractable HHE epilepsy (Shimakawa et al., August 2015), but this does not establish routine efficacy.

Trials and precision therapy

No dedicated HHE interventional trial or approved gene, cell, RNA, or targeted therapy was retrieved. Open Targets lists no associated therapeutic target for the mapped disease. (OpenTargets Search: hemiconvulsion-hemiplegia-epilepsy syndrome) Genotype-guided treatment applies only when testing identifies another disorder, such as an SCN1A-related epilepsy.

13. Prevention

Primary prevention: no method prevents idiopathic HHE with certainty. Routine immunization and prompt treatment of serious infection reduce some febrile/infectious triggers but have not been shown specifically to prevent HHE.

Secondary prevention: caregiver education and an individualized rescue plan for children with previous prolonged seizures or a fever-sensitive epilepsy may shorten seizure duration. Rapid emergency response, early benzodiazepine administration where prescribed, and escalation according to status protocols are the most rational measures.

Tertiary prevention: control recurrent seizures; provide early rehabilitation; monitor contractures, hip alignment, scoliosis, nutrition, bone health, learning, behavior, communication, and caregiver burden; evaluate drug-resistant epilepsy early for surgery.

Genetic counseling should explain that classic acquired HHE does not itself confer Mendelian recurrence risk. Recurrence counseling must instead be based on any identified underlying disorder.

14. Other species and natural disease

No well-established naturally occurring veterinary equivalent of human HHE was identified in OMIA-oriented or literature searches. Animals can develop prolonged focal seizures, unilateral brain injury, paresis, and later epilepsy, but these observations do not constitute a validated naturally occurring HHE syndrome. There is no known zoonotic transmission.

Orthologues of susceptibility genes such as SCN1A are conserved in mouse, rat, zebrafish, and other vertebrates, but those orthologues model fever-sensitive epilepsy or sodium-channel disease—not the complete acquired HHE sequence.

15. Model organisms

No single model reproduces the full human triad with high fidelity. Relevant induced systems include:

• Rodent prolonged-status models using kainate, pilocarpine, electrical stimulation, or hyperthermia to study excitotoxicity, edema, neuronal death, gliosis, and epileptogenesis.
• Immature-animal febrile-seizure/status models, which address developmental susceptibility and the interaction between temperature and seizure injury.
• SCN1A-deficient mouse or zebrafish models, useful when studying Dravet-related phenocopies, but not representative of most acquired HHE.
• Organotypic brain slices, neurons, astrocyte/microglia cultures, and blood–brain-barrier systems, which isolate excitotoxic, inflammatory, and vascular mechanisms but cannot model hemiplegia or hemispheric network reorganization.

Major limitations are that chemically induced seizures are often bilateral, lesion laterality is artificial, rodent motor lateralization differs from humans, and models rarely reproduce the age-dependent sequence of fever-triggered unilateral status, permanent contralateral hemiplegia, progressive hemiatrophy, and delayed spontaneous focal epilepsy.

Recent developments and expert assessment

The most directly relevant 2024 publication located was a radiologic case report and literature review by Essetti et al., published online in December 2024 (DOI). Another 2024 report described cerebral hemiatrophy and hemiparesis after hemiclonic status in Dravet syndrome (DOI), reinforcing the distinction between classic acquired HHE and genetically defined fever-sensitive epilepsy.

The main expert conclusion remains that HHE is best understood as a rare acquired clinicoradiologic consequence of prolonged unilateral status in a vulnerable developing brain. Current priorities are rapid status termination, serial MRI/EEG, rigorous investigation for an underlying etiology, early rehabilitation, and surgical evaluation of appropriately selected drug-resistant cases. The major research gaps are prospective incidence data, standardized diagnostic criteria, quantitative prognostic imaging, acute neuroprotection trials, and disease-specific longitudinal multi-omics.

Evidence limitations

Direct abstract quotations could not be supplied reliably for most primary studies because many HHE articles were not available as searchable full text through the retrieval system. Titles quoted above—such as “Low incidence of SCN1A genetic mutation…”—are article titles, not presented as abstract quotations. PMID values were omitted where they could not be verified; DOI links and publication months/years are supplied instead to avoid introducing incorrect identifiers. Numerical estimates should not be inferred from selected imaging or surgical cohorts, and absence of a target or trial in the queried resources is evidence of a current database gap, not proof that no experimental work exists.

References

1. (OpenTargets Search: hemiconvulsion-hemiplegia-epilepsy syndrome): Open Targets Query (hemiconvulsion-hemiplegia-epilepsy syndrome, 0 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

Artifacts

• Edison artifact artifact-00